Progress on Development of RNA Base Editing Technologies for Precision Medicines, including Axiomer® platform presented at TIDES EU by Gerard Platenburg - ProQR Therapeutics
… ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple … ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple …
… focuses on developing potential medicines using our Axiomer ® RNA editing platform technology. Strategic … drive the advancement of an early-stage technology, like Axiomer , closer to the clinic. In any global licensing and … of high unmet need Lenka van Sint Fiet, Director AxiomerAxiomer technology ProQR’s Axiomer ® platform …
This presentation reviews Axiomer editing oligonucleotides (EONs) structure activity, the potential of Axiomer platform as well as its applicability for the treatment of liver originated disorders.
Axiomer platform presentation highlighting the potential of Editing Oligonucleotides (EONs) to address liver originated disorders. Presented at the RNA Editing Gordon Research Conference on March 23, 2023 by Gerard Platenburg - ProQR Therapeutics.
This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
